chrisvoncsefalvay/vaers-outcomes huggingface dataset:
After the first dose the patient´s nerves were much more irritating and they did not feel so good; acute pain and inflammation of their nerves, they are painful all over their body,; This spontaneous case was reported by a consumer and describes the occurrence of NEURALGIA (After the first dose the patient´s nerves were much more irritating and they did not feel so good) and NEURITIS (acute pain and inflammation of their nerves, they are painful all over their body,) in a female patient of an unknown age who received mRNA-1273 (Moderna COVID-19 Vaccine) for COVID-19 vaccination.     Concurrent medical conditions included Hashimoto's disease, Thyroiditis and Neuropathy.   On an unknown date, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On an unknown date, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On an unknown date, the patient experienced NEURALGIA (After the first dose the patient´s nerves were much more irritating and they did not feel so good) and NEURITIS (acute pain and inflammation of their nerves, they are painful all over their body,). At the time of the report, NEURALGIA (After the first dose the patient´s nerves were much more irritating and they did not feel so good) and NEURITIS (acute pain and inflammation of their nerves, they are painful all over their body,) outcome was unknown.        The action taken with mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown) was unknown.       No concomitant medications were reported. Treatment details were not reported.   This case was linked to US-MODERNATX, INC.-MOD-2021-055521 (E2B Linked Report).   Reporter did not allow further contact; Sender's Comments:  US-MODERNATX, INC.-MOD-2021-055521:2nd dose
Patient reported leg/foot twitching, that did not begin until more than 48 hours after vaccination.
pt recv vax 31OCT97 & pt seen 31MAR98 w/fussiness & OM;tx w/septra;6APR98 mom reported hives-stopped septra;given DPH:pt devel blisters/scabs, a little pruritic;8APR varicelliform rash;suggestive of zoster;
Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021; Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021; This spontaneous case was reported by an emergency medical technician and describes the occurrence of PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) and EXPIRED PRODUCT ADMINISTERED (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) in a 48-year-old male patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch no. 066H21A) for COVID-19 vaccination.     No Medical History information was reported.    On 28-Jan-2022 at 1:19 PM, the patient received dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) .25 milliliter. On 28-Jan-2022 at 1:19 PM, the patient experienced EXPIRED PRODUCT ADMINISTERED (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021). On an unknown date, the patient experienced PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021). At the time of the report, PRODUCT STORAGE ERROR (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) and EXPIRED PRODUCT ADMINISTERED (Received vaccine past its 30-days Exp date Vaccines went into 2-8 C thaw state on or about 24-Dec-2021) outcome was unknown.        For mRNA-1273 (Moderna COVID-19 Vaccine) (Unknown), the reporter did not provide any causality assessments.   Patient ethnicity was reported. No concomitant medication information was provided. This vaccine was administered up until its manufacturing expiry date of 04-Apr-2022.  No treatment medication information was given.   This case was linked to MOD-2022-542869 (Patient Link).
About a week after receiving, second dose I noticed a canker sore on my inner lip. It healed and another one appeared. Now, more than 2 weeks later, I have multiple mouth sores inside my lips and underneath my tongue.
shooting pain from left shoulder to fingers if reaching to pick something up. went to clinic, Dr, could not detect any major problems after going to clinic it was gone in a day or two. But as of yet I still get shooting sensation in shoulder area up back of my neck. They last as long as for instance, a bug bite etc. I had MRI in June to see if I had a pinched nerve , but I guess nothing was found-
Clinical varicella when sibling had illness. New lesions developed over a week, 2 days of fever. No scars but was covered with lesions.
48 hours after the vaccine, patient had a drop in glucose down to 40 which triggered grand mal seizure. Admitted to the hospital for 2 days, thought it was possibly due to UTI, however because of how soon it was to the vaccine I wanted to report it just in case it were linked.
Client began having lip and right eye swelling, as well as broke out in a rash to his face, right hip and right lower back the evening of his immunization. Had a dose of BENADRYL at home before bedtime.  Came in to clinic to speak with this nurse 07/13/17 and showed rash and swelling. Recommended physician visit.
VIS given and discussed, no concerns voiced;  Pt instructed to stay in clinic area for 30 minutes after receiving vaccine due to history of anaphylaxis to latex. Patient had epi pen in her purse. Patient experienced diaphoresis and light headedness approximately 15 minutes after receiving vaccine. Was able to walk over to exam table and layed down supine position. Patient appeared pale and diaphoretic. Patient agreed to use her own epi pen from her purse. NP gave her 1 mg epinephrine with her own epi pen from her purse in her right thigh. Blood pressure checked immediately after giving epinephrine, which was 118/78. Heart rate 104; oxygen saturation 94%. Ambulance called and arrived approximately 30 minutes after patient receiving vaccine. Patient denied wanting benadryl to be given and stated she felt a lot better, but felt dizzy if she tried to sit up. Stated that she feels that way when she uses her epi pen. Ambulance arrived within 10 minutes of giving epinephrine. IV started and taken to the hospital.
This spontaneous report as received from a healthcare worker refers to 3 or 4 patients of unknown age and gender. Medical history and concurrent conditions were not reported. On an unknown date the patient was vaccinated with VARIVAX 1350 U. Dose, route, lot number and expiration date were not reported. No co-suspect and concomitant therapies were reported. The healthcare worker reported that 3 or 4 patients received VARIVAX that had been stored improperly at 14 degrees F. to 17 degrees F. for an extended unspecified amount of time (on an unknown date). No adverse effect reported. The healthcare worker also mentioned that they had PPD (manufacturer unspecified) in an open vial that had been in use longer than indicated in the prescribing information for the product. Additional information has been requested.
Patient had complaints of swelling, itching and pain at the injection site. The injection site was warm to the touch with erythema measuring  80 mm x 70 mm and an induration of 40mm. Patient stated that she had used a cold compress at the injection site. Patient was referred to Urgent Care.
Chart reviewed: note dated 5/17/00. PT with local reaction, 10x20 cm of right upper arm included swelling, erythema, heat
Tinnitus - immediately following vaccinations - on going. Fatigue - tachycardic, dyspnea, dysphagia - treated x2 week. Tingling (nerve) of extremities - on going. Tx: Prednisone, albuterol, acetazolimide.
Edema in both hands and feet with 24 hours of second vaccine,has not resolved as of 17May2021; This is a spontaneous report from a contactable consumer (patient). A non-pregnant 50-year-old female patient received her second dose of BNT162B2 (PFIZER-BIOTECH COVID-19 VACCINE, solution for injection, Lot number: EN6201) administered on the right arm on 19Feb2021 as 2nd dose, single dose (at the age of 50 years old) for COVID-19 immunization. The vaccine was administered in a hospital. The patient's medical history included DCIS breast cancer on 2018 and known allergies to sulfa and sensitivity to gluten. The patient previously received BNT162B2, administered on right arm on 28Jan2021 (Lot number: EL9264), at the age of 50 years old, as 1st dose, single dose for COVID-19 immunization. The patient's concomitant medication included venlafaxine hydrochloride (VENLAFAXINE XR), propranolol, levothyroxine sodium (LEVOTHYROXINE), and biotin. On 20Feb2021, the patient experienced edema in both hands and feet in 24 hours of the second vaccine. There was no treatment given on the event. The adverse event resulted to Doctor or other healthcare professional office/clinic visit. The patient has not had COVID prior to vaccine. The patient has not been COVID tested post vaccination. The outcome for the event was not recovered/not resolved as of 17May2021.
Patient began to have a headache within 1 hr after 1st Hep B vaccination.  She continued to have "bad" headache thoughout afternoon. She also had nausea and vomiting in the evening. She feels better today 11/10/10, but continues to have a dull headache. Patient received 2 pediatric doses of 0.5ml to equal 1 adult dose of 1.0ml because pharmacy was unable to secure adult doses from manufacturer.
I am also pregnant; I started getting pain in my shoulder and also in my neck; I cannot  turn my neck.; I started getting pain in my shoulder and also in my neck; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A female patient (pregnant) received bnt162b2 (BNT162B2), administration date 03Sep2021 (Batch/Lot number: unknown) as dose 2, single for covid-19 immunisation. The patient's relevant medical history and concomitant medications were not reported. Vaccination history included: Bnt162b2 (First Dose), for Covid-19 Immunization. The following information was reported: MATERNAL EXPOSURE TIMING UNSPECIFIED (non-serious) with onset 03Sep2021, outcome "unknown", described as "I am also pregnant"; ARTHRALGIA (non-serious), NECK PAIN (non-serious) all with onset 03Sep2021, outcome "not recovered" and all described as "I started getting pain in my shoulder and also in my neck"; MOBILITY DECREASED (non-serious) with onset 03Sep2021, outcome "not recovered", described as "I cannot turn my neck.".  Additional Information: Reporter seriousness for I am also pregnant; I started getting pain in my shoulder and also in my neck. Now, I cannot turn my neck was Unspecified. Consumer stated, "I have a question. I got the second vaccine today and I am also pregnant(not further clarified, Hence not captured in tab) but I was feeling fine and then, It's about an hour ago, I started getting pain in my shoulder and also in my neck. Now, I cannot turn my neck. I want to know is that normal." Further probing could not be done, As the Consumer was not willing to complete the report. Patient demographics, Product details, Event details, Medical history were unknown. Limited information available over the call. Consumer was informed about Pfizer Medical Information department and provided with the number.  The lot number for the vaccine, [BNT162B2], was not provided and will be requested during follow up.
pt recv vax; "scabby blister" surrounded by red ring on knee; lesion was "open & oozing";mother removed scab w/ pin;tx w/ ATBs; dx of impetigo;
Patient has been admitted to the Hospital January 11, 2020, because worsening abdominal pain, constipation.  Initially, CT scan showed possible pancreatic mass.  She tested positive for COVID-19.  She continued to be on room air.  She is fully vaccinated for COVID-19.  Repeated CT abdomen and pelvis with pancreatic protocol was negative for pancreatic mass, although followup is recommended.  Her CA-19-9 was normal.  Surgery was consulted as well as GI.  The patient tolerated her diet.  She treated with laxative with significant improvement in her abdominal pain.  Continue on PPI.  The patient was advised to avoid NSAIDs.  Initially, she was started on Rocephin and Flagyl for possible pancreatic abscess, which was ruled out later on.  She continued to be on room air.  The patient's abdominal pain improved.  Surgery cleared her for discharge.  She left in stable condition.
Redness at site (R) deltoid 2.5 inches x 2 inches. No induration.
Initial summary report received on 24 September 2013 from a non-health care professional. A patients whose gender, age, medical history and concomitant medications were not reported, received a dose of FLUZONE (lot number, route and site of vaccination was not reported) on an unspecified date. It was reported that 6 patients have received the FLUZONE. Patients experienced redness and severe swelling a couple of days after immunization. List of documents held by sender: none.
Swelling right deltoid, slight redness, knot 4-15mm at site - Restless feeling to arm.
DEATH; This spontaneous report received from a consumer via social media via a company representative concerned (5) multiple patients of an unspecified age, sex, race and ethnicity. The patients' weight, height, and medical history were not reported. The patients' all received covid-19 vaccine ad26.cov2.s (suspension for injection, route of admin, and batch number were not reported) dose and start therapy date were not reported, 1 total was administered for covid-19 prophylaxis. The batch numbers were not reported. Per procedure, no follow-up will be requested for this case. No concomitant medications were reported.  On an unspecified date, the patients' experienced death from an unknown cause of death. It was unknown whether an autopsy was performed or not. It was reported that, "I personally know 5 people that died from the vaccination". The action taken with covid-19 vaccine ad26.cov2.s was not applicable. This report was serious (Death). This case, from the same reporter is linked to 20221241416.; Sender's Comments: V0: 20221241346 -death.  Insufficient information is available to make a causality assessment. Therefore, this event is considered unclassifiable.; Reported Cause(s) of Death: UNKNOWN CAUSE OF DEATH
mild redness at injection site; Slightly more  soreness in arm after secondshot and still lingers; This is a spontaneous report received from a contactable reporter(s) (Consumer or other non HCP). The reporter is the patient.  A 67 year-old female patient (not pregnant) received bnt162b2 (BNT162B2), administered in arm left, administration date 17Mar2021 13:30 (Lot number: ER2613) at the age of 67 years as dose 2, single for covid-19 immunisation. Relevant medical history included: "allergies with several antibiotics" (unspecified if ongoing), notes: allergies with several antibiotics; "Latex allergy" (unspecified if ongoing); "Kidney stones" (unspecified if ongoing); "Osteoporosis" (unspecified if ongoing); "Under active thyroid" (unspecified if ongoing), notes: Under active thyroid. Concomitant medication(s) included: BACTRIM. Vaccination history included: Bnt162b2 (Lot number: EN6202, DOSE 1, SINGLE, Anatomical location : Arm Left, at 13:30 (at the age of 67-years-old)), administration date: 24Feb2021, when the patient was 67 years old, for COVID-19 immunisation, reaction(s): "Painful arm". The following information was reported: PAIN IN EXTREMITY (non-serious) with onset 17Mar2021 14:00, outcome "recovering", described as "Slightly more soreness in arm after secondshot and still lingers"; VACCINATION SITE ERYTHEMA (non-serious) with onset 19Mar2021, outcome "not recovered", described as "mild redness at injection site". Therapeutic measures were not taken as a result of pain in extremity, vaccination site erythema.  Additional information: The patient was not pregnant at the time of vaccination. The patient received BACTRIM for unknown indication within 2 weeks of vaccination of first shot. Prior to vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient was not tested for COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccination. Adverse events didn't result in doctor or other healthcare professional office/clinic visit, and emergency room/department or urgent care. Any treatment was not taken as a result of these events. The clinical outcome of slightly more soreness was recovering at the time of report. The clinical outcome of mild redness developed at injection site was not recovered at the time of this report.   No follow-up attempts are possible. No further information is expected.
Received influenza vaccine 10/16/2003, 3-4 days later developed intense itching - palms of hands, under arms, no external rash, has received influenza vaccine past 3 years, no new meds, no new environmental changes, no egg, latex or thimerosal allergies.
Presented to EC on 04/28/21 with shortness of breath; discharged home on 04/30/21.
Pt complain feeling fever, sweats, body ache - blisters in mouth got antiviral from MD. Acyclovir from MD.
elevated blood pressure/reading was 142 over something /reading that said 134/68; This spontaneous case was reported by a consumer and describes the occurrence of BLOOD PRESSURE INCREASED (elevated blood pressure/reading was 142 over something /reading that said 134/68) in an adult male patient who received mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (batch no. ASKU) for COVID-19 prophylaxis.     The patient's past medical history included Meniere's disease. Concurrent medical conditions included Blood pressure. Concomitant products included HYDROCHLOROTHIAZIDE, TRIAMTERENE (TRIAMTERENE/HYDROCHLOROTHIAZIDE) and CLOPIDOGREL BISULFATE (PLAVIX) for an unknown indication.    On 11-Nov-2022, the patient received fifth dose of mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (unknown route) 1 dosage form. On 16-Nov-2022,  after starting mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)), the patient experienced BLOOD PRESSURE INCREASED (elevated blood pressure/reading was 142 over something /reading that said 134/68). At the time of the report, BLOOD PRESSURE INCREASED (elevated blood pressure/reading was 142 over something /reading that said 134/68) outcome was unknown.      DIAGNOSTIC RESULTS (normal ranges are provided in parenthesis if available): On 26-Oct-2022, Blood pressure measurement: 104/70. On an unknown date, Blood pressure measurement: 134/68.     For mRNA-1273 BIVALENT .222 (MODERNA COVID-19 VACCINE, BIVALENT (ORIGINAL AND OMICRON BA.4/BA.5)) (Unknown), the reporter did not provide any causality assessments.   It was reported that patient got all 5 Moderna shots: 2 initial and 3 booster. Patient received Moderna COVID-19 Vaccine and Spikevax. All of a sudden, for the first time, he was walking with elevated blood pressure. He had been working with his doctor, who doubled the dosage of his triamterene/hydrochlorothiazide. However, he had not much impact on reducing his blood pressure. His arm was not even sore. Around 21 Oct 2022, the patient stopped taking Plavix. On 26 Oct 2022, he went for the annual physical with his PCP, and his blood pressure was 104/70. On 11 Nov 2022, he took the COVID booster shot. On 16 Nov 2022, he saw his gastroenterologist, who told him he had elevated blood pressure, but might be he was nervous about talking about his next colonoscopy. His blood pressure reading was 142 over something (unknown). The doctor thought he heard something in his heart and took a second manual reading that said 134/68. His blood pressure had been between 135-150 ever since. He stated it was a heart attack risk. There was no diagnosis of myocarditis or pericarditis.
Area pink and slightly painful.  Patient instructed to use warm compresses to area and use Motrin for pain.
Severe runny nose, congestion, severe coughing and headaches, weakness, shortness of breath, and body aches and pain.
GUILLIAN BARRE Syndrome after receiving the flu shot.  Very severe case, currently in intensive care at Hospital 2/25/09-records received for DOS 1/5-2/9/09-DC DX:Central Nervous System Vasculopoathy due to Primary versus Secondary Central Nervous System Vasculitis. Bilateral parietoccipital ischemic strokes. GUILLIAN-BARRE syndrome MILLDER FISHER variant.  Presented with uncontrollable back pain and body aches, general malaise, nausea and vomiting.PE: Gait instability, ataxia, dysmetria. Altered mental status and hypertensive crisis and autonomic instability. Patellar reflexes absent, mild left facial palsy. IVIG treatment. Mechanical ventilation and intubation with tracheostomy.  2/25/09 Hospital records, DC summary received. Service dates 1/5/09 too 2/9/09. Assessment:  Principle Diagnosis - Central Nervous System Vasculopathy due to Primary vs Secondary Central Nervous System Vasculitis. Other Diagnoses - Bilateral Parietooccipial Ischemic Strokes, Guillain-Barre Syndrome, Coronary Artery Disease, Hyperlipidemia, Hypothyroidism, Depression.  Viral gastroenteritis with abdominal discomfort and diarrhea 2 weeks prior. Patient presented with uncontrollable back pain and body aches. General malaise, nausea and vomiting. Difficulty with balance. Gait instability, ataxia, dysmetria. Altered mental status, hypertensive crisis, admitted to ICU. Patellar reflexes initially present, later patellar and Achilles reflexes absent. 1+ reflexes biceps / triceps.  Mild left facial palsy. IVIG administration. Mental status worsened. Acute bilateral strokes. Babinski present. Right thigh hematoma. Mechanical ventilation. Gastrostomy tube. Aspiration pneumonia. Follow-up: Serious vision impairment Started with flu-like symptoms about a week or two after receiving shot. Seemed to recover but still weak, stomach pain. Jan 1, 2009 - intense stomach pain, nausea, weakness, inability to walk, shoulder and back pain, dizziness. Admitted to hospital Jan 5, 2009. Flu vaccine 10/31/08, possibly also shingles vaccine.
Pt recvd vax 16JUN92 & devel swollen tongue & face & pruritic rash; seen by MD treated w/DPH & Epi;
headache which was getting more intense; 26 hours later had a low grade fever at 100 degrees; body aches; chills; very sore arm at injection site; This is a spontaneous report from a contactable Other HCP (patient). This 38-year-old female patient received the 2nd dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EL3249) via an unspecified route of administration at arm right on 10Jan2021 15:00 at single dose for covid-19 immunisation as healthcare worker. Medical history included headache. Concomitant medications were none. The patient previously received the 1st dose of bnt162b2 (PFIZER-BIONTECH COVID-19 VACCINE, lot number: EJ1685) for covid-19 immunisation. The patient received the second dose of the vaccine on 10Jan2021, and on 15Jan2021 until today (18Jan2021) she had been experiencing headache which was getting more intense. It was very unusual for her. The patient had other symptoms initially that were more on the normal range. The patient stated the headache was not normal. The patient clarified her other symptoms as: 14 hours after the injection, experienced chills and very sore arm at injection site on 11Jan2021 at 5:00 am. 26 hours later had a low grade fever at 100 degrees and body aches on 11Jan2021 at 17:00. Headache began five days post vaccination. Headaches got more intense. Headache was quite bad yesterday (17Jan2021). None of her normal medications for headache had worked. The patient had headaches in the past, but not for the length of more than a day. The patient clarified she was referring to the Pfizer COVID-19 Vaccine. Headache medications that were not working for this headache included Norco, Fiorecet, Maxalt, and Advil 100mg (with Acetaminophen, Lot: DN7580, Exp: Jan23). Outcome of the event chills, very sore arm at injection site, 26 hours later had a low grade fever at 100 degrees, body aches was unknown. Outcome of the event headache which was getting more intense was not recovered.